Ankylosing Spondylitis Market Size & Growth Forecast 2027–2036, By Segments (Distribution Channel, Drug Class), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Jump to Content
Market Size and Growth Outlook
Ankylosing Spondylitis Market size was estimated at USD 6.5 billion in 2026 and is projected to grow at a 6.65% CAGR from 2027 to 2036, reaching USD 12.37 billion by 2036. The industry revenue for 2027 is calculated at USD 6.86 billion.
Get more details on this report
Request Free Sample ReportAnkylosing Spondylitis Market Intelligence Snapshot
Regional Market Dynamics
- North America accounted for 60.19% of the market in 2026, supported by broad specialist access, widespread biologic therapy use, earlier diagnosis, and consistent long-term disease management.
- Asia Pacific is expected to grow at a 7.35% CAGR as expanding rheumatology services, improving healthcare infrastructure, and greater adoption of targeted therapies bring more patients into treatment pathways.
Segment Momentum
- Hospital Pharmacy accounted for 50.67% of the market in 2026, supported by specialist-led treatment pathways, biologic dispensing, and integrated diagnosis and care within hospital settings.
- NSAIDs are the fastest-growing drug class because they provide accessible symptom management, fit early-stage treatment needs, and support routine pain and stiffness control across a broad patient population.
Market Expansion Drivers
- Rising prevalence of inflammatory autoimmune disorders increasing demand for targeted biologic therapies.
- Advancements in IL-17 and TNF inhibitor biologics improving long-term disease management outcomes.
- Growing adoption of biomarker-driven personalized treatment approaches enhancing therapeutic precision.
Leading Market Participants
- Key players in the ankylosing spondylitis market include AbbVie Inc. (United States), Pfizer Inc. (United States), Novartis AG (Switzerland), Johnson & Johnson (United States), Eli Lilly and Company (United States), Amgen Inc. (United States), UCB S.A. (Belgium), Merck & Co., Inc. (United States), Zydus Lifesciences Limited (India), Izana Bioscience Ltd. (United Kingdom).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 6.5 billion
- 2027 Estimated Market Size: USD 6.86 billion.
- Projected Market Size: USD 12.37 billion by 2036
- Growth Forecast: 6.65% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Hospital Pharmacy (Distribution Channel) | TNF Inhibitors (Drug Class)
- Emerging Opportunity Segment: Retail Pharmacy (Distribution Channel) | Non-Steroidal Anti Inflammatory Drug (NSAID) (Drug Class)
Market Growth Drivers and Industry Trends
Rising prevalence of inflammatory autoimmune disorders increasing demand for targeted biologic therapies
The increasing prevalence and diagnosis of inflammatory autoimmune disorders will drive the ankylosing spondylitis market by expanding the patient population requiring sustained disease management. Ankylosing spondylitis is a chronic inflammatory condition that can progressively affect the spine and other joints, creating a need for therapies capable of controlling inflammation and reducing disease-related impairment. Greater clinical awareness, improved diagnosis, and increasing recognition of persistent symptoms are supporting earlier treatment initiation, while targeted biologic therapies provide options for patients who require more advanced intervention than conventional approaches.
Advancements in IL-17 and TNF inhibitor biologics improving long-term disease management outcomes
Advancements in IL-17 and TNF inhibitor biologics are strengthening the ankylosing spondylitis market as these targeted therapies address key inflammatory pathways associated with disease progression. Improvements in biologic treatment options can help physicians manage persistent symptoms, reduce inflammatory activity, and support mobility and quality of life among patients with active disease. The availability of therapies targeting distinct biological mechanisms also provides greater flexibility in treatment selection, particularly for patients who experience inadequate response or intolerance to previous therapeutic approaches.
Growing adoption of biomarker-driven personalized treatment approaches enhancing therapeutic precision
Growing adoption of biomarker-driven personalized treatment approaches will enhance the ankylosing spondylitis market by supporting more individualized decisions regarding therapy selection and disease management. Biomarkers can assist clinicians in understanding disease characteristics, identifying relevant inflammatory activity, and evaluating patient responses to treatment, helping reduce reliance on generalized treatment strategies. As diagnostic capabilities and clinical understanding of disease heterogeneity improve, personalized approaches can facilitate more targeted use of biologic therapies and closer adjustment of treatment plans according to individual patient needs.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising prevalence of inflammatory autoimmune disorders increasing demand for targeted biologic therapies | 2.20% | High | North America, Europe | High | Near Term |
| Advancements in IL-17 and TNF inhibitor biologics improving long-term disease management outcomes | 2.00% | High | North America, Europe | High | Mid Term |
| Growing adoption of biomarker-driven personalized treatment approaches enhancing therapeutic precision | 1.70% | High | North America, Asia Pacific | Emerging | Long Term |
Explore Growth Opportunities
Request Free Sample ReportRegional Demand Dynamics
North America (Largest Region)
North America accounted for the largest share of the ankylosing spondylitis market, at 60.19% in 2026, supported by advanced rheumatology care, greater disease awareness, and well-established diagnostic and treatment infrastructure. The region benefits from broader access to specialized healthcare services and growing emphasis on early identification of inflammatory disorders, which can facilitate timely intervention and long-term disease management. Continued clinical research, improving treatment options, and established reimbursement pathways also contribute to sustained demand for therapies and supportive care services.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is expected to be the fastest-growing region as healthcare systems expand their capacity for diagnosing and managing chronic inflammatory conditions. Increasing awareness of ankylosing spondylitis among patients and healthcare professionals is encouraging earlier medical consultation, while improving access to specialist care is supporting diagnosis and treatment. Expansion of healthcare infrastructure, rising investment in advanced therapies, and growing adoption of modern diagnostic approaches are creating favorable conditions for market development across the region.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation HubiScaleNascentDeveloping Advanced | |||||
| Cost-Sensitive RegioniScaleLowMedium High | |||||
| Regulatory EnvironmentiScaleRestrictiveNeutral Supportive | |||||
| Demand DriversiScaleWeakModerate Strong | |||||
| Development StageiScaleEmergingDeveloping Developed | |||||
| Adoption RateiScaleLowMedium High | |||||
| New Entrants / StartupsiScaleSparseModerate Dense | |||||
| Macro IndicatorsiScaleWeakStable Strong |
Key Country Insights
Germany 🇩🇪
Specialist Care IntegrationGermany’s ankylosing spondylitis market is supported by structured rheumatology care and adoption of biologic treatment approaches. Clinical practices are focusing on earlier disease recognition, coordinated patient management, and therapy optimization to improve outcomes for individuals with chronic inflammatory conditions.
France 🇫🇷
Integrated Patient ManagementFrance is developing ankylosing spondylitis care through coordinated rheumatology services and access to innovative treatment options. Healthcare providers are prioritizing early diagnosis, disease monitoring, and comprehensive management approaches to address long-term patient needs.
Italy 🇮🇹
Clinical Care OptimizationItaly’s ankylosing spondylitis market is focused on improving clinical pathways and expanding access to advanced therapies. Rheumatology networks are emphasizing timely diagnosis, treatment personalization, and continuous disease management to support better patient outcomes.
Japan 🇯🇵
Precision Rheumatology CareJapan is strengthening ankylosing spondylitis management through improved diagnostic awareness and personalized treatment approaches. Healthcare providers are focusing on accurate assessment, appropriate therapy selection, and integration of advanced medicines into chronic disease care pathways.
South Korea 🇰🇷
Biologic Therapy ExpansionSouth Korea’s ankylosing spondylitis market is influenced by increasing adoption of advanced biologic therapies and improved specialty care access. Healthcare stakeholders are emphasizing effective disease control, patient monitoring, and treatment strategies tailored to inflammatory arthritis management.
United States 🇺🇸
Advanced Treatment AdoptionThe U.S. ankylosing spondylitis market is characterized by continued use of advanced therapies, improved diagnosis pathways, and patient-focused disease management approaches. Healthcare providers are emphasizing targeted treatments and long-term monitoring strategies to address disease progression and improve quality of life.
Ankylosing Spondylitis Market Share (%), by Distribution Channel, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportDistribution Channel Segment Analysis: Hospital Pharmacy (Largest Segment) vs Retail Pharmacy (Fastest-Growing Segment)
Hospital pharmacy held the largest share of the ankylosing spondylitis market, accounting for 50.67% in 2026. The segment benefits from the complex treatment requirements associated with ankylosing spondylitis, where patients often require specialist evaluation, prescription management, and ongoing monitoring. Hospital pharmacies are closely integrated with rheumatology and other clinical services, making them well positioned to support access to advanced therapies and coordinated treatment pathways. This clinical integration reinforces their importance for patients receiving specialized care.
Retail pharmacy is gaining traction as treatment access becomes more decentralized and patients seek greater convenience in obtaining prescribed therapies. The expansion of outpatient care and the growing need for ongoing medication access can support pharmacy-based dispensing outside hospital settings. Greater patient familiarity with community-based medication services and increasing emphasis on convenient chronic disease management are creating favorable conditions for the retail pharmacy segment.
Drug Class Segment Analysis: TNF Inhibitors (Largest Segment) vs Non-Steroidal Anti Inflammatory Drug (NSAID) (Fastest-Growing Segment)
Holding the largest share of the ankylosing spondylitis market, the TNF inhibitor segment accounted for 61.64% in 2026. TNF inhibitors have an established role in managing inflammatory activity and are particularly important for patients whose disease requires treatment beyond conventional symptomatic approaches. Their targeted mechanism and use within specialist-led treatment strategies have strengthened their position in the therapeutic landscape, particularly as clinicians seek effective control of persistent inflammatory symptoms.
The non-steroidal anti-inflammatory drug (NSAID) segment is expanding as these medicines remain an accessible option for symptom management, particularly for patients requiring relief from pain and stiffness. NSAIDs are commonly incorporated into treatment approaches because of their established use, broad familiarity among healthcare professionals, and role in managing inflammatory symptoms. Their continued relevance is supported by the need for practical therapies that can be used across different stages of disease management.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Distribution Channel | Hospital Pharmacy, Retail Pharmacy, Others | Hospital Pharmacy | Retail Pharmacy |
| Drug Class | Non-Steroidal Anti Inflammatory Drug (NSAID), TNF Inhibitors, Others | TNF Inhibitors | Non-Steroidal Anti Inflammatory Drug (NSAID) |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Competitive Landscape and Market Positioning
Top players in the ankylosing spondylitis market:
1. AbbVie Inc. (United States)
2. Pfizer Inc. (United States)
3. Novartis AG (Switzerland)
4. Johnson & Johnson (United States)
5. Eli Lilly and Company (United States)
6. Amgen Inc. (United States)
7. UCB S.A. (Belgium)
8. Merck & Co. Inc. (United States)
9. Zydus Lifesciences Limited (India)
10. Izana Bioscience Ltd. (United Kingdom)
Increasing focus on chronic inflammatory conditions is supporting advancements in targeted therapeutic development. Biological treatment approaches are improving disease management outcomes. The ankylosing spondylitis market is evolving with stronger emphasis on personalized and long-term treatment strategies.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| AbbVie Inc. (United States) | |||||||
| Pfizer Inc. (United States) | |||||||
| Novartis AG (Switzerland) | |||||||
| Johnson & Johnson (United States) | |||||||
| Eli Lilly and Company (United States) | |||||||
| Amgen Inc. (United States) | |||||||
| UCB S.A. (Belgium) | |||||||
| Merck & Co. Inc. (United States) | |||||||
| Zydus Lifesciences Limited (India) | |||||||
| Izana Bioscience Ltd. (United Kingdom). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| UCB | Apr-25 | Secured regulatory approval in South Korea for Bimzelx, authorized for use in ankylosing spondylitis, psoriatic arthritis, and hidradenitis suppurativa. This approval facilitates the strategic expansion of UCB's immunology portfolio into the high-growth Asian market, reinforcing the company's objective to establish Bimzelx as a key therapeutic standard for chronic inflammatory diseases globally. |
| Biocad | Apr-25 | Advanced the commercialization of Seniprutug, a domestically developed ankylosing spondylitis treatment, with distribution reaching 45 Russian regions. By scaling the availability of this proprietary therapy, Biocad is strengthening its market position in Eastern Europe and demonstrating a shift toward localized production and distribution models for specialized biologics in the treatment of chronic autoimmune conditions. |
| Biocon Biologics | Apr-25 | Launched Nepexto, an etanercept biosimilar to Enbrel, in the Australian market for autoimmune conditions including ankylosing spondylitis. This expansion highlights the company’s ongoing strategy to increase its global biosimilar footprint by entering key regulated markets and providing high-quality, lower-cost alternatives to established reference products, thereby altering the competitive dynamics of local rheumatology care. |
| Sandoz | Apr-25 | Filed an antitrust lawsuit against Amgen, alleging the use of a "patent thicket" to prevent the U.S. market entry of the etanercept biosimilar Erelzi. This legal action highlights ongoing systemic barriers in the biologics market and underscores the high strategic stakes of protecting or challenging the lucrative revenue streams associated with long-standing reference products like Enbrel. |
| AbbVie | Apr-25 | Expanded reimbursement coverage in South Korea for the JAK1 inhibitor Rinvoq. This policy update significantly improves patient access to advanced therapy for ankylosing spondylitis and other inflammatory conditions. The development strengthens AbbVie’s market share in the JAK inhibitor category by removing financial barriers to treatment for a broader segment of the patient population in the region. |
| Pfizer | Apr-25 | Announced that its infliximab biosimilar, IXIFI, became available in Canada. Approved for multiple indications including ankylosing spondylitis, this launch aligns with Pfizer's strategy to expand its biosimilar portfolio and provide more affordable biologic options, increasing the total availability of TNF-inhibitor treatments in the North American market. |
| UCB | Mar-25 | Received U.S. FDA approval for Bimzelx in treating ankylosing spondylitis and non-radiographic axial spondyloarthritis. This regulatory milestone significantly expands the drug's addressable patient population and bolsters UCB's competitive position in the immunology segment, following positive Phase III clinical data demonstrating sustained long-term efficacy and safety profiles for the treatment of axial spondyloarthritis indications. |
| Alvotech and Teva Pharmaceutical Industries | Mar-25 | Received U.S. FDA approval for SIMLANDI, an interchangeable high-concentration adalimumab biosimilar. The launch aims to compete directly in the large Humira market, providing a cost-effective, biosimilar alternative for ankylosing spondylitis patients. This approval enhances competitive pressure within the TNF-inhibitor space and offers providers greater flexibility for interchangeability in clinical treatment protocols. |
| Celltrion USA | Mar-25 | Commercialized a low-WAC (wholesale acquisition cost) version of its adalimumab-aaty biosimilar. This strategic pricing initiative targets increased market adoption by improving affordability for patients with chronic conditions like ankylosing spondylitis. The move underscores the growing impact of biosimilar market entrants on the competitive landscape for reference-product immunology therapies and their role in optimizing healthcare expenditure. |
| Johnson & Johnson | Oct-24 | Assumed full commercialization responsibility for Remicade and Simponi in the UK, previously managed by Merck Sharp & Dohme. This consolidation of the commercial footprint allows Johnson & Johnson to directly manage its immunology portfolio and optimize its market strategy for these established therapeutic agents used in the treatment of axial spondyloarthritis and other chronic inflammatory autoimmune conditions. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Ankylosing Spondylitis Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Disease Severity | Mild, Moderate, Severe |
| Treatment Line | First-Line Therapy, Second-Line Therapy, Third-Line Therapy & Later |
| Route of Administration | Oral, Subcutaneous, Intravenous |
Ankylosing Spondylitis Market — Custom TOC
| Custom Chapter | Chapter Details |
|---|---|
| Patient Journey and Treatment Adoption Analysis |
|
| Biologic Therapy Access and Reimbursement Landscape |
|
| Emerging Pipeline Therapies and Innovation Outlook |
|
Need a different cut of the data?
Request Custom ResearchFrequently Asked Questions
How much revenue does the ankylosing spondylitis market generate?
What is the projected value of the ankylosing spondylitis industry by 2036?
How is rising autoimmune diagnosis shifting treatment pathways in the ankylosing spondylitis market?
How are biomarker-driven approaches and advanced biologics influencing prescribing behavior in ankylosing spondylitis care?
Why do Hospital Pharmacies dominate the ankylosing spondylitis market?
What is driving the rapid growth of NSAIDs in the ankylosing spondylitis market?
Why is North America the leading ankylosing spondylitis market?
What factors are accelerating ankylosing spondylitis market growth in Asia Pacific?
What are the prominent companies operating in the ankylosing spondylitis landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
This report was prepared by the Healthcare & Medical Devices Research Team at Fundamental Business Insights, a dedicated research group specializing in the global healthcare and medical technology industry. Our analysts continuously monitor advancements in medical technologies, clinical adoption trends, regulatory developments, reimbursement policies, healthcare infrastructure investments, competitive strategies, and evolving patient care requirements to deliver timely and reliable market intelligence. The research is developed using a structured methodology that combines primary discussions with healthcare stakeholders, company financial disclosures, regulatory publications, clinical literature, government healthcare databases, medical associations, and other authoritative secondary sources. Market estimates are validated through multiple research techniques, including top-down and bottom-up analysis, before undergoing an internal quality review to ensure accuracy, consistency, and methodological integrity prior to publication.
Delivery
Published
Available
Support
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook